Orthofix reports third-quarter loss, mixed sales and 2026 revenue outlook
+3 new sources since this summary was written
On November 9, Orthofix reported third-quarter GAAP net loss of $6.07M and diluted EPS of -$0.15, while adjusted EPS was $0.18; net sales were $207.86M. Its 10-Q showed reported sales up 1.1% year over year, while the earnings-call transcript described reported sales as up 2.3% year over year and said its referenced growth rates used a pro forma constant-currency basis excluding discontinued M6 product lines. Orthofix expects FY 2026 net sales of $825M-$830M as it reshapes its spine distributor network and product portfolio.
Why it matters
The revenue outlook sets the expected FY 2026 sales range at $825M-$830M, while the company says distributor exits, portfolio simplification and supplier delays will pressure near-term sales. The quarter also showed a narrower loss, but lower gross margin and reduced cash reserves affect the company’s financial profile.
Key facts
- 1Orthofix reported third-quarter net sales of $207.86M, representing 1.1% year-over-year growth on a reported basis. tradingview.com
- 2Third-quarter reported net loss was $6.07M versus $22.8M in the prior-year quarter, and diluted GAAP EPS was ($0.15) versus ($0.57). tradingview.com
- 3Third-quarter adjusted earnings were 18 cents per share. finance.yahoo.com
- 4Orthofix forecast full-year 2026 net sales of $825M-$830M. finance.yahoo.com
- 5Reported gross margin declined to 70.5% from 72.2%. tradingview.com
- 6Cash reserves decreased to $86.9M from $104.4M due to working-capital timing, according to the company. seekingalpha.com
Open questions
- The materials give different year-over-year sales growth figures on a reported basis: 1.1% in the 10-Q summary and 2.3% in the earnings-call transcript; the transcript also separately describes referenced growth rates as pro forma constant currency excluding discontinued M6 product lines.
- Material 7 reports Q3 sales of $208.6M, compared with $207.86M-$207.9M in the other materials, and uniquely reports a $15M 2026 European distributor benefit and a $22M MDR-related headwind.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.